JP2018197237A5 - - Google Patents

Download PDF

Info

Publication number
JP2018197237A5
JP2018197237A5 JP2018126516A JP2018126516A JP2018197237A5 JP 2018197237 A5 JP2018197237 A5 JP 2018197237A5 JP 2018126516 A JP2018126516 A JP 2018126516A JP 2018126516 A JP2018126516 A JP 2018126516A JP 2018197237 A5 JP2018197237 A5 JP 2018197237A5
Authority
JP
Japan
Prior art keywords
seq
immunogenic composition
amino acid
antigen
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018126516A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018197237A (ja
JP6666389B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2018197237A publication Critical patent/JP2018197237A/ja
Publication of JP2018197237A5 publication Critical patent/JP2018197237A5/ja
Priority to JP2020026905A priority Critical patent/JP7336402B2/ja
Application granted granted Critical
Publication of JP6666389B2 publication Critical patent/JP6666389B2/ja
Priority to JP2023133790A priority patent/JP7679431B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018126516A 2011-05-11 2018-07-03 修飾ビオチン結合タンパク質、その融合タンパク質、および用途 Active JP6666389B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2020026905A JP7336402B2 (ja) 2011-05-11 2020-02-20 修飾ビオチン結合タンパク質、その融合タンパク質、および用途
JP2023133790A JP7679431B2 (ja) 2011-05-11 2023-08-21 修飾ビオチン結合タンパク質、その融合タンパク質、および用途

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201161484934P 2011-05-11 2011-05-11
US61/484,934 2011-05-11
US201261608168P 2012-03-08 2012-03-08
US61/608,168 2012-03-08
US201261609974P 2012-03-13 2012-03-13
US61/609,974 2012-03-13

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2014510498A Division JP6366501B2 (ja) 2011-05-11 2012-05-11 修飾ビオチン結合タンパク質、その融合タンパク質、および用途

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020026905A Division JP7336402B2 (ja) 2011-05-11 2020-02-20 修飾ビオチン結合タンパク質、その融合タンパク質、および用途

Publications (3)

Publication Number Publication Date
JP2018197237A JP2018197237A (ja) 2018-12-13
JP2018197237A5 true JP2018197237A5 (enExample) 2019-02-28
JP6666389B2 JP6666389B2 (ja) 2020-03-13

Family

ID=47139675

Family Applications (7)

Application Number Title Priority Date Filing Date
JP2014510498A Active JP6366501B2 (ja) 2011-05-11 2012-05-11 修飾ビオチン結合タンパク質、その融合タンパク質、および用途
JP2014510481A Active JP6152378B2 (ja) 2011-05-11 2012-05-11 多重抗原提示免疫原性組成物、ならびにその方法および使用
JP2017105191A Active JP6502420B2 (ja) 2011-05-11 2017-05-29 多重抗原提示免疫原性組成物、ならびにその方法および使用
JP2018126516A Active JP6666389B2 (ja) 2011-05-11 2018-07-03 修飾ビオチン結合タンパク質、その融合タンパク質、および用途
JP2019052175A Pending JP2019104758A (ja) 2011-05-11 2019-03-20 多重抗原提示免疫原性組成物、ならびにその方法および使用
JP2020026905A Active JP7336402B2 (ja) 2011-05-11 2020-02-20 修飾ビオチン結合タンパク質、その融合タンパク質、および用途
JP2023133790A Active JP7679431B2 (ja) 2011-05-11 2023-08-21 修飾ビオチン結合タンパク質、その融合タンパク質、および用途

Family Applications Before (3)

Application Number Title Priority Date Filing Date
JP2014510498A Active JP6366501B2 (ja) 2011-05-11 2012-05-11 修飾ビオチン結合タンパク質、その融合タンパク質、および用途
JP2014510481A Active JP6152378B2 (ja) 2011-05-11 2012-05-11 多重抗原提示免疫原性組成物、ならびにその方法および使用
JP2017105191A Active JP6502420B2 (ja) 2011-05-11 2017-05-29 多重抗原提示免疫原性組成物、ならびにその方法および使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019052175A Pending JP2019104758A (ja) 2011-05-11 2019-03-20 多重抗原提示免疫原性組成物、ならびにその方法および使用
JP2020026905A Active JP7336402B2 (ja) 2011-05-11 2020-02-20 修飾ビオチン結合タンパク質、その融合タンパク質、および用途
JP2023133790A Active JP7679431B2 (ja) 2011-05-11 2023-08-21 修飾ビオチン結合タンパク質、その融合タンパク質、および用途

Country Status (13)

Country Link
US (9) US9499593B2 (enExample)
EP (4) EP3881836A1 (enExample)
JP (7) JP6366501B2 (enExample)
KR (4) KR20140146993A (enExample)
CN (4) CN108714212B (enExample)
AU (2) AU2012253359B2 (enExample)
BR (2) BR112013028892B1 (enExample)
CA (2) CA2835628C (enExample)
ES (2) ES2864764T3 (enExample)
MX (2) MX2013013112A (enExample)
RU (2) RU2632651C2 (enExample)
WO (2) WO2012155007A1 (enExample)
ZA (2) ZA201308461B (enExample)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101139590B (zh) * 2000-02-28 2012-07-18 启龙股份公司 奈瑟球菌蛋白质的杂交表达
US9125863B2 (en) * 2008-05-22 2015-09-08 Children's Medical Center Corporation Synergistic immunogenic fusion protein-polysaccharide conjugate
WO2011112906A2 (en) 2010-03-12 2011-09-15 Children's Medical Center Corporation Novel immunogens and methods for discovery and screening thereof
ES2864764T3 (es) 2011-05-11 2021-10-14 Childrens Medical Center Composición inmunogénica que presenta múltiples antígenos, y métodos y usos de la misma
US10500283B2 (en) * 2011-05-30 2019-12-10 National Institute Of Immunology Vaccine composition capable of inducing memory antibody response from single point immunization
WO2013043643A1 (en) * 2011-09-21 2013-03-28 St. Jude Children's Research Hospital Live, attenuated streptococcus pneumoniae strain and vaccine for protection against pneumococcal disease
US9274430B2 (en) 2012-10-10 2016-03-01 Arizona Board Of Regents On Behalf Of Arizona State University Systems and devices for molecule sensing and method of manufacturing thereof
WO2014124228A1 (en) 2013-02-07 2014-08-14 Children's Medical Center Corporation Protein antigens that provide protection against pneumococcal colonization and/or disease
US9981997B2 (en) 2013-10-31 2018-05-29 Arizona Board Of Regents On Behalf Of Arizona State University Chemical reagents for attaching affinity molecules on surfaces
WO2016044588A1 (en) 2014-09-19 2016-03-24 The Regents Of The University Of Michigan Staphylococcus aureus materials and methods
CN104548101B (zh) * 2015-01-31 2017-02-22 广东海大畜牧兽医研究院有限公司 一种诱导哺乳动物乳腺黏膜产生IgA的免疫增强剂及其制备方法和应用
CN105646681B (zh) * 2016-01-21 2021-07-16 浙江海隆生物科技有限公司 一种奶牛金黄色葡萄球菌α-溶血素亚单位疫苗的制备方法及应用
WO2017180587A2 (en) 2016-04-11 2017-10-19 Obsidian Therapeutics, Inc. Regulated biocircuit systems
US20190119332A1 (en) * 2016-05-04 2019-04-25 The Children's Medical Center Corporation Methods to purify avidin-like proteins and fusion proteins thereof
US10751398B2 (en) * 2016-10-07 2020-08-25 Loyola University Chicago Inflammasome activators and methods of use to treat tumors
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
KR20190103256A (ko) 2016-12-30 2019-09-04 수트로박스, 인코포레이티드 비자연 아미노산을 갖는 폴리펩타이드-항원 접합체
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
US20180161433A1 (en) * 2017-03-22 2018-06-14 Timothy Andrew Erickson Size tunable microbial mimetics for immunotherapy of thyroid carcinomas and solid tumors
CN110730670A (zh) * 2017-03-28 2020-01-24 儿童医疗中心有限公司 基于多抗原提呈系统(maps)的金黄色葡萄球菌疫苗、免疫原性组合物以及它们的用途
WO2018217564A1 (en) * 2017-05-22 2018-11-29 The Children's Medical Center Corporation Combined vaccine against mycobacterium tuberculosis
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
CN111132691A (zh) 2017-06-10 2020-05-08 创赏有限公司 提供改善的免疫原性和亲合力的具有二价或多价缀合物多糖的多价缀合物疫苗
JP2020525540A (ja) 2017-06-23 2020-08-27 ノソコミアル ヴァクスィーン コーポレイション 免疫原性組成物
WO2019018635A1 (en) * 2017-07-19 2019-01-24 Children's Medical Center Corporation COMPOSITIONS AND METHODS FOR TREATING DISEASES ASSOCIATED WITH IMPRESSIVE FAULT
US11541110B2 (en) 2017-10-13 2023-01-03 The Research Foundation For The State University Of New York Comprehensive vaccine design for commensal disease progression
US12053486B2 (en) 2018-03-09 2024-08-06 Therazure LLC Compositions for the treatment of infections in feet
CN108339115B (zh) * 2018-05-11 2020-07-10 武汉博沃生物科技有限公司 使用重组载体蛋白的肺炎球菌联合疫苗及其制备方法
WO2019241315A1 (en) 2018-06-12 2019-12-19 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
JP2021535921A (ja) 2018-09-12 2021-12-23 アフィニバックス、インコーポレイテッド 多価肺炎球菌ワクチン
JP7535791B2 (ja) * 2018-09-12 2024-08-19 ザ チルドレンズ メディカル センター コーポレーション 肺炎球菌融合タンパク質ワクチン
WO2020086742A1 (en) 2018-10-24 2020-04-30 Obsidian Therapeutics, Inc. Er tunable protein regulation
CN109400704B (zh) * 2018-11-14 2020-07-21 珠海泰诺麦博生物技术有限公司 一种抗金黄色葡萄球菌α-溶血素的抗体及其应用
KR20210149251A (ko) 2019-03-08 2021-12-08 옵시디안 테라퓨틱스, 인크. 조율가능한 조절을 위한 인간 탄산 무수화효소 2 조성물 및 방법
WO2020223240A1 (en) * 2019-04-29 2020-11-05 The Broad Institute, Inc. Affinity-based multiplexing for live-cell monitoring of complex cell populations
EP3983538A1 (en) 2019-06-12 2022-04-20 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
WO2020252404A1 (en) 2019-06-12 2020-12-17 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
CN111518822B (zh) * 2019-07-02 2022-08-09 江南大学 一种硫酸软骨素abc裂解酶突变体及其分泌表达的方法
JP2021029171A (ja) * 2019-08-23 2021-03-01 国立大学法人東京農工大学 ブレビバチルス菌を用いた表層提示法
US20220348937A1 (en) 2019-09-06 2022-11-03 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
WO2021092206A1 (en) * 2019-11-05 2021-05-14 Beth Israel Deaconess Medical Center, Inc. Mycobacterial compositions and biomarkers for use in treatment and monitoring of therapeutic responsiveness
US20230340402A1 (en) * 2019-12-27 2023-10-26 Amolifescience Co., Ltd. Cell culture substrate and manufacturing method thereof
JP2023508478A (ja) * 2019-12-27 2023-03-02 アモライフサイエンス カンパニー リミテッド 細胞培養基材及びその製造方法
EP4192499A4 (en) 2020-08-10 2024-09-25 Inventprise, Inc. Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24f
WO2022053016A1 (zh) * 2020-09-14 2022-03-17 神州细胞工程有限公司 通过糖-冠状病毒rbd抗原缀合物提高免疫原性的方法
US20240197853A1 (en) * 2021-04-06 2024-06-20 The Board Of Trustees Of The University Of Illinois Multivalent cholera multiepitope fusion antigen (mefa) and methods of use
US20230233667A1 (en) 2021-09-08 2023-07-27 Affinivax, Inc. Coronavirus vaccine
WO2023039223A1 (en) 2021-09-09 2023-03-16 Affinivax, Inc. Multivalent pneumococcal vaccines
WO2023069278A1 (en) * 2021-10-20 2023-04-27 Fina Biosolutions, Llc Chemical reagents for the activation of polysaccharides in the preparation of conjugate vaccines
MX2024005327A (es) 2021-11-02 2024-05-21 Arvada Therapeutics Inc Composiciones y metodos de dsg2.
US20250064910A1 (en) * 2021-12-02 2025-02-27 The Children's Medical Center Corporation A maps vaccine targeting salmonella enterica serovars
WO2023192997A2 (en) * 2022-03-31 2023-10-05 The Children's Medical Center Corporation Immunogenic compositions for b-cell recall response to a polysaccharide antigen
WO2024081906A1 (en) * 2022-10-14 2024-04-18 The Children's Medical Center Corporation A maps vaccine targeting group b streptococcus (gbs)
WO2024081871A1 (en) * 2022-10-14 2024-04-18 The Children's Medical Center Corporation Shigella multiple antigen presenting immunogenic composition and fusion proteins thereof
IL321062A (en) 2022-11-22 2025-07-01 Pfizer Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CN115819624B (zh) * 2022-12-16 2023-12-15 深圳华腾生物医药科技有限公司 一种重组融合蛋白及其制备方法和应用
CN120826235A (zh) * 2023-03-16 2025-10-21 艾芬尼维克斯公司 免疫原性组合物
AU2024246082A1 (en) 2023-03-30 2025-10-16 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CN121057590A (zh) 2023-04-14 2025-12-02 辉瑞公司 包含缀合荚膜糖抗原的免疫原性组合物及其用途
WO2024224266A1 (en) 2023-04-24 2024-10-31 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024229176A1 (en) 2023-05-04 2024-11-07 Affinivax, Inc. Rhizavidin variants
TW202527906A (zh) 2023-09-14 2025-07-16 美商輝瑞股份有限公司 包含經結合之肺炎鏈球菌莢膜醣抗原之佐劑化致免疫性組成物及其用途
WO2025080776A2 (en) * 2023-10-13 2025-04-17 The Children's Medical Center Corporation Vaccine compositions comprising sialic acid binding domain (sbd) proteins and use thereof to enhance immune response
WO2025186705A2 (en) 2024-03-06 2025-09-12 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2025193903A1 (en) 2024-03-15 2025-09-18 Affinivax, Inc. Pneumococcal polysaccharide compositions and uses thereof
WO2025219908A2 (en) 2024-04-19 2025-10-23 Pfizer Inc. Media and fermentation methods for polysaccharide production in bacterial cell culture
CN118421577B (zh) * 2024-06-28 2024-10-01 华南理工大学 酪氨酸酶突变体及其用途

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US244420A (en) 1881-07-19 Stove pipe threadeb and beader
US3887699A (en) 1969-03-24 1975-06-03 Seymour Yolles Biodegradable polymeric article for dispensing drugs
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
PH19942A (en) 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4673641A (en) 1982-12-16 1987-06-16 Molecular Genetics Research And Development Limited Partnership Co-aggregate purification of proteins
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
DE3413608A1 (de) 1984-04-11 1985-10-24 Hoechst Ag, 6230 Frankfurt Implantierbare zubereitungen von regulatorischen peptiden mit gesteuerter freisetzung und verfahren zu ihrer herstellung
US4879236A (en) 1984-05-16 1989-11-07 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
WO1988001513A1 (fr) 1986-08-28 1988-03-10 Teijin Limited Complexe d'anticorps cytocide et procede de production
NZ224422A (en) 1987-05-05 1990-11-27 Molecular Eng Ass Composition adapted for intranasal immunisation against viral infection comprising a glycoprotein complexed with a lipid
US5229490A (en) 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
US5179007A (en) 1989-07-07 1993-01-12 The Texas A & M University System Method and vector for the purification of foreign proteins
FR2664905B1 (fr) 1990-07-18 1994-08-12 Agronomique Inst Nat Rech Baculovirus modifie, son procede d'obtention, et vecteurs d'expression obtenus a partir dudit baculovirus.
US5516657A (en) 1992-05-11 1996-05-14 Cambridge Biotech Corporation Baculovirus vectors for expression of secretory and membrane-bound proteins
US5390111A (en) 1993-11-12 1995-02-14 General Electric Company Method and system for processing cone beam data for reconstructing free of boundary-induced artifacts a three dimensional computerized tomography image
WO1995017515A1 (en) 1993-12-23 1995-06-29 University Technologies International Inc. Methods of expressing proteins in insect cells and methods of killing insects
IL112372A (en) 1994-02-07 2001-08-26 Res Dev Foundation Non-viral vector for the delivery of genetic information to cells
EP0814833B1 (en) 1995-03-22 2003-05-28 Henry M. Jackson Foundation For The Advancement Of Military Medicine Producing immunogenic constructs using soluble carbohydrates activated via organic cyanylating reagents
SE506793C2 (sv) 1996-09-19 1998-02-09 Atlas Copco Rocktech Ab Kopplingsstycke för användning vid samtidig jord- och/eller bergborrning med en övre rotationsslaganordning och en undre slaganordning
WO1998018931A2 (en) 1996-10-31 1998-05-07 Human Genome Sciences, Inc. Streptococcus pneumoniae polynucleotides and sequences
US6087328A (en) 1997-04-24 2000-07-11 Henry M. Jackson Foundation For The Advancement Of Military Medicine Coupling of unmodified proteins to haloacyl or dihaloacyl derivatized polysaccharides for the preparation of protein-polysaccharide vaccines
US7060458B1 (en) * 1997-08-14 2006-06-13 Wyeth Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics
WO1999012416A1 (en) 1997-09-09 1999-03-18 The Trustees Of Columbia University In The City Of New York T-independent conjugate-vaccines
SE9900496D0 (sv) 1999-02-12 1999-02-12 Pharmatrix Ab Vaccine formulation
US6398774B1 (en) 1999-09-29 2002-06-04 Heska Corporation Intranasal delivery system
US8246945B2 (en) 2000-04-06 2012-08-21 University Of Arkansas Methods and reagents for decreasing clinical reaction to allergy
US6919187B2 (en) 2000-04-21 2005-07-19 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US20020051794A1 (en) 2000-08-09 2002-05-02 Alk-Abello A/S Novel parenteral vaccine formulations and uses thereof
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
WO2003094960A2 (en) 2002-05-14 2003-11-20 Chiron Srl Mucosal combination vaccines for bacterial meningitis
EP1603950A2 (en) * 2003-03-17 2005-12-14 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
EP2336357A1 (en) 2003-04-15 2011-06-22 Intercell AG S. pneumoniae antigens
AU2004255526A1 (en) 2003-05-07 2005-01-20 Aventis Pasteur, Inc. Method of enhanced immunogenicity to meningococcal vaccination
EP1670509A4 (en) * 2003-09-03 2007-10-31 Dendritherapeutics Inc MULTIPLEX VACCINES
US7556814B2 (en) 2003-10-23 2009-07-07 Karp Nelson M Immunogenic compositions comprising UV-irradiated, psoralen-inactivated, desialated human immunodeficiency virus (HIV) devoid of CD55 and CD59 in the viral membrane
EP1708741B1 (en) 2003-12-24 2016-03-30 Aduro Biotech Recombinant nucleic acid molecules encoding fusion proteins comprising antigens and bacterial secretory signal polypeptides, expression cassettes, and bacteria, and methods of use thereof
WO2005103073A2 (en) 2004-04-27 2005-11-03 Intercell Ag Td antigens
GB0410220D0 (en) * 2004-05-07 2004-06-09 Kirkham Lea Ann Mutant pneumolysin proteins
CA2576083A1 (en) 2004-08-18 2006-02-23 Joel Weiner Protein production method utilizing yebf
FI20041396A0 (fi) * 2004-10-29 2004-10-29 Vesa Pekka Hytoenen Uudet mikrobiavidiinit
US20090028891A1 (en) 2004-11-11 2009-01-29 Queensland University Of Technology Chlamydia Antigens and Uses Thereof
GB0428394D0 (en) * 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
JP2008530037A (ja) 2005-02-11 2008-08-07 エース バイオサイエンシズ エー/エス 表面に位置したStreptococcuspneumoniaeのポリペプチド
US20090148894A1 (en) * 2005-08-15 2009-06-11 Broedel Sheldon E Methods for optimizing the secretion of protein in prokaryotes
CN101287488B (zh) 2005-09-01 2013-01-30 诺华疫苗和诊断有限两合公司 含血清群c脑膜炎球菌的多价疫苗
MX2008007292A (es) 2005-12-08 2008-10-17 Univ Louisville Res Found Composiciones inmunoestimuladoras y metodos.
WO2007081583A2 (en) 2006-01-04 2007-07-19 Children's Medical Center Corporation Anti-pneumococcal preparations and methods of use
US7943133B2 (en) 2006-02-02 2011-05-17 Boston Biocom Llc Mesothelin antibody protein fusions and methods of use
US20080032340A1 (en) 2006-06-09 2008-02-07 University Of Arizona Peptide motifs for binding avidin or neutravidin
WO2007149982A2 (en) 2006-06-22 2007-12-27 The Brigham And Women's Hospital, Inc. Diagnosis of autoimmune disease
EP2041175A4 (en) * 2006-06-23 2011-03-16 Augmenta Biolog Llc TARGETED IMMUNOJUGATE
US7452985B2 (en) 2006-08-17 2008-11-18 Visgeneer, Inc. Human Ron-related gene variant associated with cancers
WO2008152448A2 (en) 2006-12-21 2008-12-18 Emergent Product Development Uk Limited Streptococcus proteins, and their use in vaccination
CN100579152C (zh) 2007-01-29 2010-01-06 华为技术有限公司 一种播放集团彩铃的方法、系统及装置
EP2468869B1 (en) * 2007-01-31 2015-03-18 Pfenex Inc. Bacterial leader sequences for increased expression
US8128939B2 (en) 2007-04-13 2012-03-06 The Board Of Regents Of The University Of Oklahoma Mutants of cholesterol-dependent cytolysins and uses thereof
US9610339B2 (en) 2007-06-26 2017-04-04 Glaxosmithkline Biologicals, S.A. Vaccine comprising Streptococcus pneumoniae capsular polysaccharide conjugates
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
WO2009020553A2 (en) 2007-08-03 2009-02-12 President And Fellows Of Harvard College Chlamydia antigens
EP2176291A1 (en) 2007-08-10 2010-04-21 Wacker Chemie AG Expression of full length igg and secretion into the culture medium of prokaryotic cells
CA2697538C (en) 2007-08-31 2019-02-12 University Of Chicago Methods and compositions related to immunizing against staphylococcal lung diseases and conditions
BRPI0923649A2 (pt) 2008-12-24 2016-01-19 Netherlands Vaccine Inst polipeptídeos de pneumolisina (ply) de streptococcus pneumoniae modificados.
EP2208787A1 (en) * 2009-01-19 2010-07-21 Université de Liège A recombinant alpha-hemolysin polypeptide of Staphylococcus aureus, having a deletion in the stem domain and heterologous sequences inserted
CA2758490C (en) 2009-04-14 2023-05-02 Novartis Ag Compositions for immunising against staphylococcus aureus
US8828953B2 (en) 2009-04-20 2014-09-09 NaZura BioHealth, Inc. Chemosensory receptor ligand-based therapies
MX2012000158A (es) 2009-06-29 2012-06-08 Genocea Biosciences Inc Vacunas y composiciones contra streptococcus pneumoniae.
CN101797381B (zh) 2010-01-29 2012-05-23 中国人民解放军第三军医大学 乙肝病毒抗原与路易斯寡糖的复合物及其制备方法和应用
WO2011137354A2 (en) 2010-04-30 2011-11-03 Augmenta Biologicals, Llc Delivery proteins
ES2864764T3 (es) 2011-05-11 2021-10-14 Childrens Medical Center Composición inmunogénica que presenta múltiples antígenos, y métodos y usos de la misma
WO2014018904A1 (en) 2012-07-26 2014-01-30 Genocea Biosciences, Inc. Fused antigen vaccines and compositions against streptococcus pneumoniae
WO2014124228A1 (en) 2013-02-07 2014-08-14 Children's Medical Center Corporation Protein antigens that provide protection against pneumococcal colonization and/or disease
CN110730670A (zh) 2017-03-28 2020-01-24 儿童医疗中心有限公司 基于多抗原提呈系统(maps)的金黄色葡萄球菌疫苗、免疫原性组合物以及它们的用途
JP2021535921A (ja) 2018-09-12 2021-12-23 アフィニバックス、インコーポレイテッド 多価肺炎球菌ワクチン

Similar Documents

Publication Publication Date Title
JP2018197237A5 (enExample)
JP2020079300A5 (enExample)
JP2014517835A5 (enExample)
Kumar et al. Bacterial protein toll-like-receptor agonists: a novel perspective on vaccine adjuvants
CA2759583C (en) A tuberculosis tb vaccine to prevent reactivation
Mäkelä Vaccines, coming of age after 200 years
JP2023162283A5 (enExample)
Sijts et al. Two Listeria monocytogenes CTL epitopes are processed from the same antigen with different efficiencies.
JP2014514363A5 (enExample)
RU2013154706A (ru) Модифицированный биотин-связывающий белок, слитые белки на его основе и их применение
JP2011524737A5 (enExample)
Mader et al. Endotoxicity does not limit the use of bacterial ghosts as candidate vaccines
JP2013502918A5 (enExample)
JP2015536134A5 (enExample)
JP2004526405A5 (enExample)
Newman et al. Immunological and formulation design considerations for subunit vaccines
JP2012532626A5 (enExample)
JP2003519668A5 (enExample)
JP2013523084A5 (enExample)
ATE328085T1 (de) Identifizierung und klonierung eines mycobakterien antigens der einer heparin- bindenden hemaglutinin entspricht
de Velasco et al. Synthetic peptides representing T-cell epitopes act as carriers in pneumococcal polysaccharide conjugate vaccines
Ferreira et al. A highly effective component vaccine against nontyphoidal Salmonella enterica infections
JP2012526519A5 (enExample)
JP2004503217A5 (enExample)
Del Giudice Hsp70: a carrier molecule with built-in adjuvanticity